Manuela Jorquera

Manuela Jorquera

Auto-generated profile, based on publicly available information

Manuela Jorquera

Servicio de Radiología, Hospital Clínico San Carlos, Madrid, España

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in Brain
Verified
Journal Article
Closed access
PDF file
Maria Diez-CirardaMaria Diez-Cirarda
Maria Diez-Cirarda
MYMiguel Yus
Miguel Yus
NGNatividad Gómez-Ruiz
Natividad Gómez-Ruiz
CPCarmen Polidura
Carmen Polidura
LGLidia Gil-Martínez
Lidia Gil-Martínez
Jordi A. Matias-GuiuJordi A. Matias-Guiu
Jordi A. Matias-Guiu
Brain changes have been reported in the first weeks after SARS-CoV-2 infection. However, limited literature exists about brain alterations in post-COVID syndrome, a condition increasingly associated with cognitive impairment. The present study aimed to evaluate brain functional and structural alterations in patients with post-COVID syndrome, and assess whether these brain alterations were related to cognitive dysfunction. Eighty-six patients with post-COVID syndrome and 36 healthy controls were recruited and underwent neuroimaging acquisition and a comprehensive neuropsychological assessment. Cognitive and neuroimaging examinations were performed 11 months after the first symptoms of SARS-CoV-2. Whole-brain functional connectivity analysis was performed. Voxel-based morphometry was performed to evaluate grey matter volume, and diffusion tensor imaging was carried out to analyse white-matter alterations. Correlations between cognition and brain changes were conducted and Bonferroni corrected. Post-COVID syndrome patients presented with functional connectivity changes, characterized by hypoconnectivity between left and right parahippocampal areas, and between bilateral orbitofrontal and cerebellar areas compared to controls. These alterations were accompanied by reduced grey matter volume in cortical, limbic and cerebellar areas, and alterations in white matter axial and mean diffusivity. Grey matter volume loss showed significant associations with cognitive dysfunction. These cognitive and brain alterations were more pronounced in hospitalized patients compared to non-hospitalized patients. No associations with vaccination status were found. The present study shows persistent structural and functional brain abnormalities 11 months after the acute infection. These changes are associated with cognitive dysfunction and contribute to a better understanding of the pathophysiology of the post-COVID syndrome.

24 March 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
CDCristina Delgado-Alonso
Cristina Delgado-Alonso
MVMaria Valles-Salgado
Maria Valles-Salgado
ADAlfonso Delgado-Álvarez
Alfonso Delgado-Álvarez
MYMiguel Yus
Miguel Yus
NGNatividad Gómez-Ruiz
Natividad Gómez-Ruiz
JMJordi A. Matías-Guiu
Jordi A. Matías-Guiu

1 May 2013 in World Neurosurgery
Verified
Journal Article
Closed access
RPRuth Prieto
Ruth Prieto
JPJosé M. Pascual
José M. Pascual
ISIssa Subhi-Issa
Issa Subhi-Issa
MJManuela Jorquera
Manuela Jorquera
MYMiguel Yus
Miguel Yus
RMRoberto Martínez
Roberto Martínez

1 May 2005 in Spine
Verified
Journal Article
Closed access
SRSantiago Gil Robles Robles
Santiago Gil Robles Robles
CSCristobal Saldaña
Cristobal Saldaña
GBGregorio R. Boto
Gregorio R. Boto
AMArmando Martinez
Armando Martinez
AZAlvaro Perez Zamarron
Alvaro Perez Zamarron
PMPedro Mata
Pedro Mata
Spinal ependymoma is a benign central nervous system tumor described as an intramedullary lesion more frequently located at the conus medullaris. It has been described exceptionally in the literature as an intradural extramedullary tumor. Presentation of an extremelly rare location and evolution of extremedullary ependymoma and discussion of its probable origin, differential diagnosis, treatment options, and follow-up. This case demonstrates an unusual location of a benign ependymal tumor in the extramedullary space with a total resection, which recurred in a lower level with a malignant transformation with the same extramedullary location. The authors present the case of a 47-year-old woman with a subacute spinal cord dysfunction and an intradural extramedullary D2–D3 tumor mimicking meningioma or neurinoma. At surgery, an encapsulated intradural extramedullary mass was found, but neither dural attachment nor medullary infiltration was present. After complete resection, anatomic-pathologic studies confirmed that the lesion was a benign classic ependymoma. Good neurologic outcome was achieved, and no residual tumor was present at magnetic resonance imaging (MRI) control performed at 3 and 9 months later. One year after surgery, a new intradural extramedullary tumor was found at the D4 level without recurrence at D2. The patient was operated on again, but at this time the histologic study showed an anaplastic ependymoma with a proliferation index of 25% measured by Ki-67. Whole central nervous system radiotherapy was performed. All of the previously reported cases of spinal intradural extramedullary ependymomas carried out a benign course. The case we are reporting is the first one in which malignant transformation occurred. This tumor should be taken into account in the differential diagnosis of intradural extramedullary lesions. Moreover, close follow-up is recommended for this unusual location of ependymomas.

14 March 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
IGInés González González-Suárez
Inés González González-Suárez
LALuis Rodríguez De Antonio
Luis Rodríguez De Antonio
AOAida Orviz
Aida Orviz
SMSara Moreno-García
Sara Moreno-García
MVMaría D Valle-Arcos
María D Valle-Arcos
COCelia Oreja-Guevara
Celia Oreja-Guevara
Introduction: Natalizumab (NTZ) is an effective drug for the treatment of relapsing‐remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after drug cessation. Our aim was to describe the clinical and radiological features of the rebound phenomenon.Material and Methods: Patients switched fromNTZto Fingolimod (FTY) who had presented a rebound after discontinuation were selected. Clinical and magnetic resonance imaging (MRI) data were collected.Results: FourJCvirus positive patients were included. The mean disease duration was 9.5 years (SD: 4.12) with a mean time of 3.1 years onNTZ. All patients startedFTYwithin 3–4 months. Neurological deterioration started in a mean time of 3.5 months (SD: 2.08) with multifocal involvement: 75% motor disturbances, 50% cognitive impairment, 25% seizures. The average worsening in Expanded Disability Status Scale [EDSS] was of 3.25 points (SD: 2.33). TheMRIshowed a very large increase in T2 and gadolinium‐enhanced lesions (mean: 23.67,SD: 18.58). All patients received 5 days of IV methylprednisolone, one patient required plasma exchange. All the patients presented neurological deterioration with anEDSSworsening of 1.13 points (SD: 0.48). After the rebound three patients continued treatment withFTY, only one patient restartedNTZ.Conclusion: Discontinuation ofNTZtreatment may trigger a severe rebound with marked clinical and radiological worsening. A very careful evaluation of benefit‐risk should be considered beforeNTZwithdrawal, and a close monitoring and a short washout period is recommended after drug withdrawal.

20 December 2018 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Jordi A. Matias-GuiuJordi A. Matias-Guiu
Jordi A. Matias-Guiu
ACAna Cortés-Martínez
Ana Cortés-Martínez
PMPaloma Montero
Paloma Montero
VPVanesa Pytel
Vanesa Pytel
TMTeresa Moreno-Ramos
Teresa Moreno-Ramos
Jorge Matias-GuiuJorge Matias-Guiu
Jorge Matias-Guiu
The Paced Auditory Serial Addition Test (PASAT) is a useful cognitive test in patients with multiple sclerosis (MS), assessing sustained attention and information processing speed. However, the neural underpinnings of performance in the test are controversial. We aimed to study the neural basis of PASAT performance by using structural magnetic resonance imaging (MRI) in a series of 242 patients with MS. PASAT (3-s) was administered together with a comprehensive neuropsychological battery. Global brain volumes and total T2-weighted lesion volumes were estimated. Voxel-based morphometry and lesion symptom mapping analyses were performed. Mean PASAT score was 42.98 ± 10.44; results indicated impairment in 75 cases (31.0%). PASAT score was correlated with several clusters involving the following regions: bilateral precuneus and posterior cingulate, bilateral caudate and putamen, and bilateral cerebellum. Voxel-based lesion symptom mapping showed no significant clusters. Region of interest–based analysis restricted to white matter regions revealed a correlation with the left cingulum, corpus callosum, bilateral corticospinal tracts, and right arcuate fasciculus. Correlations between PASAT scores and global volumes were weak. PASAT score was associated with regional volumes of the posterior cingulate/precuneus and several subcortical structures, specifically the caudate, putamen, and cerebellum. This emphasises the role of both cortical and subcortical structures in cognitive functioning and information processing speed in patients with MS.